The pharmaceutical industry is seeing a shift toward personalized medicines, and it’s evolving to deliver this via some exciting new tools.

A prime example is the recent announcement of ATMPS’ Hataali blockchain platform being successfully tested with the University Hospitals Birmingham NHS Foundation Trust’s system interface; denoting it as the world’s first blockchain solution for Advanced Therapeutic Medicinal Products (ATMP).

Taking the digital shift in a different direction, within the life sciences industry TraceLink has now managed to leverage cloud technologies to create the world’s largest network of pharmaceutical supply chain partners and allow them to connect seamlessly.

Add the fact that scientists from Rice University Bioengineering have used deep-learning methods to develop their Metabolite Translator, a computer system that can predict what the in-vivo metabolites of a drug could be in order to identify its potential toxicity, and it’s clear to see that times are changing!

In an industry that is notoriously non-digital, these bold developments are inevitably the foundation blocks of a new and exciting chapter in our history.

Follow us on LinkedIn to stay abreast of all the latest news and events.

Additional News

  • 9 July 2025

    HER-096: A possible breakthrough in Parkinson’s disease treatment

    This testimonial highlights our collaboration with Herantis Pharma on the analytical development and nonclinical support for HER-096, a promising candidate in the fight against Parkinson’s disease.

  • 9 June 2025

    Ensuring Success in Buccal Film Development: The Midazolam Film Case Study

    Fast, Simple, Effective: Unlocking the Potential of Midazolam Films

  • 15 May 2025

    From Analytical Similarity to Clinical Data: Tailoring Evidence for Biosimilar Approval

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar.